Alogliptin (SYR-322)DPP-4 inhibitor,potent and highly selective CAS# 850649-61-5 |
- PK 44 phosphate
Catalog No.:BCC2366
CAS No.:1017682-65-3
- NVP DPP 728 dihydrochloride
Catalog No.:BCC2365
CAS No.:247016-69-9
- Sitagliptin phosphate monohydrate
Catalog No.:BCC2111
CAS No.:654671-77-9
- Alogliptin Benzoate
Catalog No.:BCC1341
CAS No.:850649-62-6
- Trelagliptin
Catalog No.:BCC2014
CAS No.:865759-25-7
- DPPI 1c hydrochloride
Catalog No.:BCC2363
CAS No.:866396-34-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 850649-61-5 | SDF | Download SDF |
| PubChem ID | 11450633 | Appearance | Powder |
| Formula | C18H21N5O2 | M.Wt | 339.39 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Alogliptin,SYR322 | ||
| Solubility | >14.8mg/mL in DMSO | ||
| Chemical Name | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile | ||
| SMILES | CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N | ||
| Standard InChIKey | ZSBOMTDTBDDKMP-OAHLLOKOSA-N | ||
| Standard InChI | InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Alogliptin is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. | |||||
| Targets | DPP-4 | |||||
| IC50 | < 10 nM | |||||
| Cell experiment: [1] | |
| Cell lines | U937 histiocyte |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reacting condition | 5 nM, 48h, inhibited cell proliferation 1 nM, 48h, inhibited MMP-1 secretion |
| Applications | Alogliptin inhibited cell proliferation by 53% at concentration of 5 nM. At 1 nM, alogliptin inhibited MMP-1 secretion significantly, suggesting that the inhibitory effect of alogliptin on MMP is not associated with that on cell proliferation. |
| Animal experiment : [2] | |
| Animal models | Zucker fa/fa rats |
| Dosage form | Eight-week-old male Zucker fa/fa rats were divided into 5 groups based on body weight and fasting plasma glucose levels and administered vehicle alone (0.5% carboxymethylcellulose) or alogliptin at 0.3, 1, 3, or 10 mg/kg by single bolus oral gavage (5 ml/kg dose volume). At 30 min postdose, rats were given a glucose solution (1 g/kg, 2ml/kg dose volume). Blood glucose concentrations were analyzed up to 90min after glucose load using the Accu-Chek glucometer and plasma insulin concentrations were analyzed up to 60 min after glucose load using an insulin ELISA kit. |
| Application | Early-phase insulin secretion was increased after a single dose of alogliptin compared with vehicle alone. Alogliptin increased about 1.5, 1.5, and 1.8 fold for the 0.3, 1, and 3 mg/kg doses. Significant decreases in blood glucose excursion were observed for all alogliptin doses compared with vehicle alone after an oral glucose load. Mean baseline-adjusted blood glucose AUC0–90 min was decreased by approximately 31%, 37%, and 41% for the 0.3, 1, and 3 mg/kg doses, respectively. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Ta N N, Li Y, Schuyler C A, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis, 2010, 213(2): 429-435. [2] Lee B, Shi L, Kassel D B, et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European journal of pharmacology, 2008, 589(1): 306-314. | |
Alogliptin (SYR-322) Dilution Calculator
Alogliptin (SYR-322) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | 58.9293 mL | 73.6616 mL |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | 11.7859 mL | 14.7323 mL |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL | 5.8929 mL | 7.3662 mL |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5893 mL | 1.1786 mL | 1.4732 mL |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.5893 mL | 0.7366 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Abstract
Alogliptin is not only an inhibitor of DPP-4 that raises postprandial levels of glucagon-like peptide 1 resulting in insulin secretion and glucose homeostasis but also a safe and tolerable anti-diabetic agent showing a significant reduction in HdA1c when used alone or with other anti-diabetic agents.
Abstract
Alogliptin, a DPP-4 inhibitor, has been reviewed for its pharmacology, pharmacokinetics, safety and efficacy in the managment of T2DM.
Abstract
The cardiovascular profile of alogliptin, a DPP-4 inhibitor, has been evaluated due to increased CV risk associated with the treatment of type 2 diabetes.
Abstract
Alogliptin, a DPP-4 inhibitor, has been assessed for its cardiovascular outcomes in patients with type 2 diabetes and a recent acute coronary syndrome.
Abstract
Alogliptin has been evaluated for its efficacy and safety in elderly T2DM patients who have received treatment for more than a year.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Alogliptin (also known as SYR-322), is a novel, orally-available and highly selective quinazolinone-based inhibitor of dipeptidyl peptidase-4 (DPP-4), a serine aminopeptidase catalyzing the cleavage of peptides, that potently inhibits human DPP-4 in vitro with 50% inhibition concentration IC50 value of 6.9 nM and barely exhibits any inhibition towards the closely related serine proteases, including DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidas and tryptase (IC50 > 100,000 nM for all). Alogliptin prevents DPP-4-catalyzed degradation of GLP-1 and GIP, which regulate concentrations of blood glucose by stimulating glucose-dependent insulin secretion, and hence is being investigated in the treatment of type 2 diabetes.
Reference
Bumsup Lee, Lihong Shi, Daniel B. Kassel, Tomoko Asakawa, Koji Takeuchi and Ronald J. Christopher. Pharmacokinetic, pharmacodynamics, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European Journal of Pharmacology 589 (2008) 306-314
- Apigenin 5-O-neohesperidoside
Catalog No.:BCN6840
CAS No.:850630-40-9
- Norviburtinal
Catalog No.:BCN4399
CAS No.:85051-41-8
- Fmoc-Arg(Tos)-ol
Catalog No.:BCC2588
CAS No.:850330-29-9
- Rosin
Catalog No.:BCN5969
CAS No.:85026-55-7
- Cinchonain IIb
Catalog No.:BCN7738
CAS No.:85022-68-0
- Shikonofuran A
Catalog No.:BCN2826
CAS No.:85022-66-8
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
- Afatinib dimaleate
Catalog No.:BCC1330
CAS No.:850140-73-7
- Sulfatinib
Catalog No.:BCC8811
CAS No.:1308672-74-3
- 5-Methoxysuberenone
Catalog No.:BCN3638
CAS No.:85011-58-1
- Methyl 1,6-dihydroxy-3-methylxanthone-8-carboxylate
Catalog No.:BCN7473
CAS No.:85003-85-6
- Altrenogest
Catalog No.:BCC4479
CAS No.:850-52-2
- Alogliptin Benzoate
Catalog No.:BCC1341
CAS No.:850649-62-6
- GSK269962A
Catalog No.:BCC5178
CAS No.:850664-21-0
- BX517(PDK1 inhibitor2)
Catalog No.:BCC6391
CAS No.:850717-64-5
- NBI-98782
Catalog No.:BCC4277
CAS No.:85081-18-1
- Cinchonain IIa
Catalog No.:BCN7716
CAS No.:85081-23-8
- Danoprevir (RG7227)
Catalog No.:BCC2106
CAS No.:850876-88-9
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- THIP hydrochloride
Catalog No.:BCC6803
CAS No.:85118-33-8
- 2-Methoxystypandrone
Catalog No.:BCN4400
CAS No.:85122-21-0
- PF9 tetrasodium salt
Catalog No.:BCC7854
CAS No.:851265-78-6
- Phospho-Glycogen Synthase Peptide-2 (substrate)
Catalog No.:BCC5747
CAS No.:851366-97-7
- (S)-4-Carboxy-3-hydroxyphenylglycine
Catalog No.:BCC6600
CAS No.:85148-82-9
A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.[Pubmed:19427871]
Life Sci. 2009 Jul 17;85(3-4):122-6.
AIMS: Loss of efficacy over time or secondary failure occurs somewhat often and remains a major concern of sulfonylurea (SU) therapy. In this study, we investigated the benefits of alogliptin, an oral, potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in a rat model exhibiting SU secondary failure. MAIN METHODS: Neonatally streptozotocin-induced diabetic rats (N-STZ-1.5 rats), a non-obese model of type 2 diabetes, were used in these studies. The effects of alogliptin on DPP-4 activity and glucagon-like peptide 1 (GLP-1) concentration were determined by measuring their levels in plasma. In addition, the effects of alogliptin on an oral glucose tolerance test were investigated by using an SU secondary failure model. KEY FINDINGS: Alogliptin dose dependently suppressed plasma DPP-4 activity leading to an increase in the plasma active form of GLP-1 and improved glucose excursion in N-STZ-1.5 rats. Repeated administration of glibenclamide resulted in unresponsiveness or loss of glucose tolerance typical of secondary failure. In these rats, alogliptin exhibited significant improvement of glucose excursion with significant increase in insulin secretion. By contrast, glibenclamide and nateglinide had no effect on the glucose tolerance of these rats. SIGNIFICANCE: The above findings suggest that alogliptin was effective at improving glucose tolerance and therefore overcoming SU induced secondary failure in N-STZ-1.5 rats.
